Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Infection
Published in: Infection 4/2011

01-08-2011 | Case Report

Successful switch to tenofovir after suboptimal response to entecavir in an immunocompromised patient with chronic hepatitis B and without genotypic hepatitis B virus resistance

Authors: C. Sarrecchia, V. Svicher, A. Volpi, R. Salpini, L. Ceccarelli, P. Sordillo, A. Bertoli, C. F. Perno, M. Andreoni

Published in: Infection | Issue 4/2011

Login to get access

Abstract

We report a case of an immunocompromised patient affected by chronic hepatitis B virus (HBV) with high basal HBV viremia (>8 log10 IU/ml) who failed an entecavir regimen, despite the absence of primary or secondary drug resistance mutations. The patient achieved sustained virological success (serum HBV DNA <12 IU/ml) when tenofovir was added to the treatment. This case highlights the difficulty in choosing an optimal therapy in such specific conditions and supports the concept of tailoring therapy (including combination regimens) on the basis of the particular conditions of each individual patient.
Literature
1.
Mutimer D, Dusheiko G, Barrett C, Grellier L, Ahmed M, Anschuetz G, Burroughs A, Hubscher S, Dhillon AP, Rolles K, Elias E. Lamivudine without HBIg for prevention of graft reinfection by hepatitis B: long-term follow-up. Transplantation. 2000;70:809–15.PubMedCrossRef
2.
Dienstag JL, Goldin RD, Heathcote EJ, Hann HW, Woessner M, Stephenson SL, Gardner S, Gray DF, Schiff ER. Histological outcome during long-term lamivudine therapy. Gastroenterology. 2003;124:105–17.PubMedCrossRef
3.
Yuen MF, Wong DK, Sablon E, Yuan HJ, Sum SM, Hui CK, Chan AO, Wang BC, Lai CL. Hepatitis B virus genotypes B and C do not affect the antiviral response to lamivudine. Antivir Ther. 2003;8:531–4.PubMed
4.
Chang TT, Gish RG, De Man R, Gadano A, Sollano J, Chao YC, Lok AS, Han KH, Goodman Z, Zhu J, Cross A, DeHertogh D, Wilber R, Colonno R, Apelian D; BEHoLD AI463022 Study Group. A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. N Engl J Med. 2006;354:1001–10.PubMedCrossRef
5.
Lai CL, Shouval D, Lok AS, Chang TT, Cheinquer H, Goodman Z, DeHertogh D, Wilber R, Zink RC, Cross A, Colonno R, Fernandes L; BEHoLD AI463027 Study Group. Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. N Engl J Med. 2006;354:1011–20.PubMedCrossRef
6.
Colonno RJ, Rose RE, Pokornowski K, Baldick CJ, Eggers B, Xu D, Cross A, Tenney DJ. Four year assessment of entecavir resistance in nucleoside naive and lamivudine refractory patients. J Hepatol. 2007;46:S294.CrossRef
7.
European Association for the Study of the Liver. EASL Clinical Practice Guidelines: management of chronic hepatitis B. J Hepatol. 2009;50:227–42.CrossRef
8.
Marcellin P, Heathcote EJ, Buti M, Gane E, De Man RA, Krastev Z, Germanidis G, Lee SS, Flisiak R, Kaita K, Manns M, Kotzev I, Tchernev K, Buggisch P, Weilert F, Kurdas OO, Shiffman ML, Trinh H, Washington MK, Sorbel J, Anderson J, Snow-Lampart A, Mondou E, Quinn J, Rousseau F. Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B. N Engl J Med. 2008;359:2442–55.PubMedCrossRef
9.
Chen CJ, Yang HI, Iloeje UH; REVEAL-HBV Study Group. Hepatitis B virus DNA Levels and outcomes in chronic hepatitis B. Hepatology. 2009;49:S72–84.PubMedCrossRef
10.
Rodriguez-Frias F, Jardi R, Schaper M, Buti M, Ferrer-Costa C, Tabernero D, Homs M, Esteban R. Adefovir for chronic hepatitis B treatment: identification of virological markers linked to therapy response. Antivir Ther. 2008;13:991–9.PubMed
11.
Chen WN, Oon CJ. Hepatitis B virus surface antigen (HBsAg) mutants in Singapore adults and vaccinated children with high anti-hepatitis B virus antibody levels but negative for HBsAg. J Clin Microbiol. 2000;38:2793–4.PubMed
12.
Khokhar A, Afdhal NH. Therapeutic strategies for chronic hepatitis B virus infection in 2008. Am J Med. 2008;121:S33–44.PubMedCrossRef
13.
Rodriguez C, Chevaliez S, Pallier C, Pawlotsky JM. Ultra-deep sequencing analysis demonstrates pre-existence of HBV resistance substitutions at baseline in patients who subsequently develop clinical resistance. In: Proceedings of the 17th Conference on Retroviruses and Opportunistic Infections (CROI 2010), San Francisco, CA, February 2010, paper # 170LB.
14.
Bagaglio S, Porrino L, Lazzarin A, Morsica G. Molecular characterization of occult and overt hepatitis B (HBV) infection in an HIV-infected person with reactivation of HBV after antiretroviral treatment interruption. Infection. 2010;38:417–21.PubMedCrossRef
15.
Bagaglio S, Bianchi G, Danise A, Porrino L, Uberti-Foppa C, Lazzarin A, Castagna A, Morsica G. Longitudinal evaluation of occult Hepatitis B infection in HIV-1 infected individuals during highly active antiretroviral treatment interruption and after HAART resumption. Infection. 2011;39:121–6. Epub 2011 Mar 22.PubMedCrossRef
16.
Solmone M, Vincenti D, Prosperi MC, Bruselles A, Ippolito G, Capobianchi MR. Use of massively parallel ultradeep pyrosequencing to characterize the genetic diversity of hepatitis B virus in drug-resistant and drug-naive patients and to detect minor variants in reverse transcriptase and hepatitis B S antigen. J Virol. 2009;83:1718–26.PubMedCrossRef
17.
Margeridon-Thermet S, Shulman NS, Ahmed A, Shahriar R, Liu T, Wang C, Holmes SP, Babrzadeh F, Gharizadeh B, Hanczaruk B, Simen BB, Egholm M, Shafer RW. Ultra-deep pyrosequencing of hepatitis B virus quasispecies from nucleoside and nucleotide reverse-transcriptase inhibitor (NRTI)-treated patients and NRTI-naive patients. J Infect Dis. 2009;199:1275–85.PubMedCrossRef
Metadata
Title
Successful switch to tenofovir after suboptimal response to entecavir in an immunocompromised patient with chronic hepatitis B and without genotypic hepatitis B virus resistance
Authors
C. Sarrecchia
V. Svicher
A. Volpi
R. Salpini
L. Ceccarelli
P. Sordillo
A. Bertoli
C. F. Perno
M. Andreoni
Publication date
01-08-2011
Publisher
Springer-Verlag
Published in
Infection / Issue 4/2011
Print ISSN: 0300-8126
Electronic ISSN: 1439-0973
DOI
https://doi.org/10.1007/s15010-011-0127-3

Other articles of this Issue 4/2011

Infection 4/2011 Go to the issue

Images in infection

A case of tuberculous meningitis with multiple intracranial tuberculomas and miliary tuberculosis and choroid tubercles

Correspondence

Anemia and community-acquired pneumococcal pneumonia

Brief Report

Suspicion of viral gastroenteritis does improve compliance with hand hygiene

Clinical and Epidemiological Study

Lipopolysaccharide binding protein, interleukin-6 and C-reactive protein in acute gastrointestinal infections: value as biomarkers to reduce unnecessary antibiotic therapy

Brief Report

Healthcare-acquired infections in rehabilitation units of the Lombardy Region, Italy

Clinical and Epidemiological Study

De-escalation of antimicrobials in the treatment of bacteraemia due to antibiotic-sensitive pathogens in immunocompetent patients

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits